Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Equity Income (2021 - 2024)

Tarsus Pharmaceuticals has reported Equity Income over the past 4 years, most recently at -$6000.0 for Q2 2024.

  • Quarterly results put Equity Income at -$6000.0 for Q2 2024, down 140.0% from a year ago — trailing twelve months through Dec 2024 was -$591000.0 (down 328.19% YoY), and the annual figure for FY2024 was -$591000.0, down 328.19%.
  • Equity Income for Q2 2024 was -$6000.0 at Tarsus Pharmaceuticals, up from -$585000.0 in the prior quarter.
  • Over the last five years, Equity Income for TARS hit a ceiling of $420000.0 in Q4 2023 and a floor of -$591000.0 in Q4 2021.
  • Median Equity Income over the past 4 years was -$65000.0 (2023), compared with a mean of -$108272.7.
  • Biggest five-year swings in Equity Income: skyrocketed 624.14% in 2023 and later plummeted 800.0% in 2024.
  • Tarsus Pharmaceuticals' Equity Income stood at -$591000.0 in 2021, then skyrocketed by 109.81% to $58000.0 in 2022, then skyrocketed by 624.14% to $420000.0 in 2023, then tumbled by 101.43% to -$6000.0 in 2024.
  • The last three reported values for Equity Income were -$6000.0 (Q2 2024), -$585000.0 (Q1 2024), and $420000.0 (Q4 2023) per Business Quant data.